The manufacturing and marketing licenses for the commercial use of Prussian blue insoluble formulations have been granted to Scott-Edil Pharmacia Limited, Himachal Pradesh and Skanttr Lifescience, Gujarat by Drugs Controller General of India. <br />”<br />”It is one of the critical medicines listed by the World Health Organisation for radiological and nuclear emergencies. Defence Ministry said, the drug will be available under the trade name of Pru-DecorpTM and PruDecorp-MG. <br />”<br />”The formulations are used for decontamination of Cesium and Thallium and its Active Pharmaceutical Ingredient. The drug has been developed by the industry based on the technology of Institute of Nuclear Medicine and Allied Sciences, Delhi, a laboratory of Defence Research and Development Organisation (DRDO).<br />”&nbsp;<br />”<span style="color: #222222;">Secretary, Department of Defence Research and Development and Chairman DRDO Dr. Samir V Kamat has congratulated the Organisation as well as the industry on this achievement. He stated that the development of these drug formulations under the Technology Development Fund project is a successful endeavour of the DRDO for promoting the industry to achieve the vision of Aatmanirbhar Bharat.</span><br />